3SBio, a China-based biotechnology company, has acquired the entire share capital of Sirton Pharmaceuticals, located in Villa Guardia, Italy, from First Shanghai, a financial services provider.

"Expanding 3SBio's footprint in key developed markets is a core strategic objective for 3SBio," said Dr. Jing Lou, chairman and CEO of 3SBio. "With a team of experienced professionals and a client base of leading pharmaceutical companies, Sirton provides 3SBio with a solid base to manufacture, develop and market pharmaceutical products in Europe."

Sirton produces injectable pharma products, including pre-filled syringes, liquid vials, freeze-dried vials and ampoules, and pharmaceutical development services including lyophilization process development, analytical method development and validation, stability studies and manufacturing of clinical study materials.

Sirton's customers are international pharmaceutical companies, including Mylan, Sandoz, Sanofi Avenis France, Crinos and UCB Pharma. Sirton also develops and produces generic pharmaceutical products including zoledronic acid, through Ingenerics, a joint venture with Tripharma.

3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Since its founding in 1993, 3SBio's R&D efforts have resulted in four NDAs for biological medicines, including TPIAO, the first rhTPO approved worldwide.